This reflects the state of play as of early 2026: States that cover GLP-1s for obesity treatment (fee-for-service): Arkansas, Colorado, Connecticut, Delaware, Illinois, Louisiana, Massachusetts, Minnesota, New Mexico, New York, Oregon, Virginia, Washington approximately 13 states total as of January 2026
For context on category pricing: brand-name Wegovy carries a list price of approximately $1,349 to $1,850 per month without insurance
GIP (glucose-dependent insulinotropic polypeptide) Receptor Agonist Mounjaro also targets the hormone alongside GLP-1, which helps with feeling full and blood sugar control, but it works slightly differently from GLP-1
115, 2020 [15] D
Individual variables such as age, starting weight, and other health complications influenced the outcomes